Study results emphasize the need for psychological management and mental disorder screening as part of standard cancer care.
This triple drug regimen became the first FDA-approved all-oral combination for multiple myeloma in the relapsed/refractory setting.
Clinicians seek stronger collaboration between cardiology and oncology as well as evidence-based treatment guidelines.
Dr Jabbour discusses clinical decision making for chronic myeloid leukemia and the high price of newly approved drugs in an interview with Cancer Therapy Advisor.
Recent research has indicated the potential for IL-12 therapy to be effective in combination with new and emerging biologics including other immunomodulatory drugs.
Acute kidney injury incidence after radical nephrectomy and partial nephrectomy is increasing.
From Oncology Nurse Advisor
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Myeloma: Daratumumab Monotherapy Induces Rapid, Deep, Durable Responses
- Oophorectomy Associated With 30% Increased Risk of Colorectal Cancer
- Body Mass Index Associated With Colorectal Cancer Mortality Risk
- Health Care Workplace Violence: "Underreported, Tolerated, and Largely Ignored"
- Necitumumab Not Effective for Non-EGFR-expressing NSCLC
- Breast Cancer (Recurrent or Metastatic) Treatment Regimens
- New Surgical System Offers Alternative to Lumpectomy Wire Localization
- Testicular Cancer Treatment Regimens
- Arsenic Levels in Drinking Water Tied to Elevated Bladder Cancer Risk
- Four Quality Measures May Lengthen Survival in Patients With NSCLC
- Rectal Cancer Treatment Regimens
- Mental Disorder Risk High Among Patients With Cancer During Treatment and Before Diagnosis
- Refractory Myeloma: Study Supports Pomalidomide + Low-dose Dex as a Standard of Care
- Anemia Before SBRT Linked to Poor Survival in Stage I NSCLC
- Sex Discrepancy May Explain Lower OS in Women With Advanced Bladder Cancer